IP Library Granted Patent US 11,034,694
Granted Patent B2
US 11,034,694 · App. 17/020,122 · Granted Jun 15, 2021

Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists

Inventors: Neelu Kaila (Lexington, MA); Ian Linney (Saffron Walden, GB); Stuart Ward (Saffron Walden, GB); Grant Wishart (Saffron Walden, GB); Ben Whittaker (Saffron Walden, GB); Alexandre Cote (West New York, NJ); Jeremy Robert Greenwood (Brooklyn, NY); Abba Leffler (Bronx, NY); Steven K. Albanese (Brooklyn, NY); Daniel L. Severance (San Diego, CA)
Assignee: Nimbus Saturn, Inc.
C07D471/04C07D401/14C07D487/04C07D495/04C07D498/04C07D519/00C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,694
App. No.
17/020,122
Granted
Jun 15, 2021
Kind
B2
Abstract

The present invention provides compounds of formula I: or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof. The present invention also provides methods for the inhibition of HPK1 and methods for the treatment of HPK1-mediated disorders.

Claims (44)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle and a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

21. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical composition of claim 12 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (15)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: WISHART, GRANT
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 055981/0730 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: KAILA, NEELU
To: NIMBUS DISCOVERY, INC.
Reel/Frame 055156/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: WHITTAKER, BEN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 055156/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: COTE, ALEXANDRE
To: SCHRÖDINGER, INC.
Reel/Frame 055156/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: GREENWOOD, JEREMY ROBERT
To: SCHRÖDINGER, INC.
Reel/Frame 055156/0229 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: LEFFLER, ABBA
To: SCHRÖDINGER, INC.
Reel/Frame 055156/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: ALBANESE, STEVEN K.
To: SCHRÖDINGER, INC.
Reel/Frame 055156/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: SEVERANCE, DANIEL L.
To: SCHRÖDINGER, INC.
Reel/Frame 055156/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: CHARLES RIVER LABORATORIES, INC.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 055156/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: SCHRÖDINGER, INC.
To: SCHRÖDINGER, L.L.C.
Reel/Frame 055156/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: SCHRÖDINGER, L.L.C.
To: NIMBUS DISCOVERY, INC.
Reel/Frame 055156/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: NIMBUS DISCOVERY, INC.
To: NIMBUS SATURN, INC.
Reel/Frame 055156/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: LINNEY, IAN
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LTD.
Reel/Frame 055223/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: WARD, STUART
To: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
Reel/Frame 055223/0928 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED
To: CHARLES RIVER LABORATORIES, INC.
Reel/Frame 055224/0079 →
Continuity (4)
Continuation 17018591 · Sep 11, 2020
Provisional Application 63032070 · May 29, 2020
Provisional Application 62900152 · Sep 13, 2019
Related Publication 20210078998A1 · Mar 18, 2021
Cited By (4)
US 12,215,105 US 12,252,488 US 12,258,346 US 12,466,841